From Bedside to Bench: How Clinical Mass Spectrometry is Turning Traditional Human Health Research Upside Down

Mon 9:00 AM - Plenary Session

Dayan Goodenowe Phenomenome

Dayan Goodenowe, Phenomenome

Virtually all human diseases are diagnosed using human-centric methods from simple questionnaires to complex imaging devices. However, the current model of disease target discovery and validation involves creating an animal model of a human disease, discovering targets within that model, developing therapeutics that work within the model and then translating these therapeutics back into humans. Unfortunately, the mechanism by which the disease is created in the animal model can be very different from that which creates the disease in humans. This results in therapeutics focused on symptomatic relief. Using a human serum-based discovery metabolomics approach we have successfully identified combination diagnostic biomarkers and therapeutic targets for Alzheimer’s Disease, Colon Cancer, and Autism. These clinically validated bedside targets have then been extensively investigated epidemiologically and at the bench as to their role in the etiology of each disease. This approach has led to first-in-class diagnostic and therapeutic products based upon true human causal mechanisms of these diseases.

Email: d.goodenowe@phenomenome.com

---